Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn:
“This article highlights technical and procedural considerations needed to support DCTs and identifies areas for trial innovation.
By making DCTs and technology platforms participant-centric and continuing to advance opportunities for innovation, researchers may accelerate scientific discovery, help participants feel their contributions are meaningful, and foster long-term trust in the biomedical research process.”
Title: Participants as Partners in Decentralized Clinical Trials
Journal: NEJM Evidence
Authors: Paul A. Harris, Alex C. Cheng
More posts featuring Vivek Subbiah on OncoDaily.